We are live on ! Find out more
BBA

Baker Bros. Advisors Portfolio holdings

AUM $17.4B
1-Year Est. Return 131.5%
This Fund
S&P 500
This Quarter Est. Return
-0.11%
1 Year Est. Return
+131.5%
3 Year Est. Return
+336.81%
5 Year Est. Return
+553.16%
10 Year Est. Return
+4,134.93%
AUM
$7.97B
AUM Growth
-$817M
Cap. Flow
-$41.1M
Cap. Flow %
-0.52%
Top 10 Hldgs %
77.13%
Holding
94
New
12
Increased
15
Reduced
7
Closed
7

Top Buys

Rank Stock Value
1
RVMD icon
Revolution Medicines
RVMD
+$71.2M
2
BCYC
Bicycle Therapeutics
BCYC
+$67M
3
EWTX icon
Edgewise Therapeutics
EWTX
+$43.3M
4
ABCL icon
AbCellera Biologics
ABCL
+$23.6M
5
DNLI icon
Denali Therapeutics
DNLI
+$21.1M

Top Sells

Rank Stock Value
1
MRTX
Mirati Therapeutics, Inc. Common Stock
MRTX
+$242M
2
IMCR icon
Immunocore
IMCR
+$69M
3
GRCL
Gracell Biotechnologies Inc. American Depositary Shares
GRCL
+$20.9M
4
DAWN
Day One Biopharmaceuticals
DAWN
+$14.6M
5
SPRY icon
ARS Pharmaceuticals
SPRY
+$11M

Sector Composition

Rank Sector Weight
1 Healthcare 99.96%
2 Financials 0.04%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
SERA icon
26
Sera Prognostics
SERA
$81.5M
$49.5M 0.62%
5,434,399
– –
PRLD icon
27
Prelude Therapeutics
PRLD
$375M
$48M 0.6%
10,123,824
– –
IDYA icon
28
IDEAYA Biosciences
IDYA
$3.42B
$46.6M 0.58%
1,062,123
– –
STOK icon
29
Stoke Therapeutics
STOK
$1.84B
$45.5M 0.57%
3,368,443
+1,338,309
+66% +$8.11M
XENE icon
30
Xenon Pharmaceuticals
XENE
$6.1B
$42.8M 0.54%
993,679
– –
IGMS
31
DELISTED
IGM Biosciences
IGMS
$39.5M 0.49%
4,088,322
+397,311
+11% +$4.6M
CERS icon
32
Cerus
CERS
$573M
$36.8M 0.46%
19,477,339
– –
GLUE icon
33
Monte Rosa Therapeutics
GLUE
$1.82B
$34.7M 0.43%
4,916,095
– –
CELC icon
34
Celcuity
CELC
$4.06B
$33.5M 0.42%
1,552,478
+1,017,000
+190% +$16.2M
BMEA icon
35
Biomea Fusion
BMEA
$88.2M
$31.5M 0.4%
2,108,949
– –
KRYS icon
36
Krystal Biotech
KRYS
$10.7B
$30.2M 0.38%
169,934
– –
SANA icon
37
Sana Biotechnology
SANA
$888M
$23.8M 0.3%
2,380,949
+380,949
+19% +$2.85M
NGNE icon
38
Neurogene
NGNE
$670M
$23.2M 0.29%
456,015
+2,499
+0.6% +$83.5K
VERV
39
DELISTED
Verve Therapeutics
VERV
$22.5M 0.28%
1,691,530
– –
TCRX icon
40
TScan Therapeutics
TCRX
$48.5M
$22.1M 0.28%
2,784,792
– –
ADAP
41
DELISTED
Adaptimmune Therapeutics
ADAP
$17M 0.21%
10,787,022
-182,260
-2% -$220K
IMVT icon
42
Immunovant
IMVT
$7.93B
$13.7M 0.17%
425,009
– –
TSVT
43
DELISTED
2seventy bio
TSVT
$13.4M 0.17%
2,497,526
– –
FATE icon
44
Fate Therapeutics
FATE
$275M
$13.3M 0.17%
+1,818,181
New +$11.3M
XNCR icon
45
Xencor
XNCR
$1.45B
$12.1M 0.15%
545,431
+300,000
+122% +$6.48M
TSHA icon
46
Taysha Gene Therapies
TSHA
$1.61B
$11.5M 0.14%
4,004,756
– –
DBVT
47
DBV Technologies
DBVT
$817M
$10.9M 0.14%
1,461,426
– –
CLDX icon
48
Celldex Therapeutics
CLDX
$2.95B
$10.4M 0.13%
247,644
– –
RLAY icon
49
Relay Therapeutics
RLAY
$4B
$9.63M 0.12%
1,160,117
– –
INSM icon
50
Insmed
INSM
$22.4B
$9.31M 0.12%
343,000
– –
1
2
3 4

Similar funds

FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
CM
Caption Management Oklahoma City, Oklahoma $17.1B AUM 70.99% 1-Year Est. Return
MCM
MAI Capital Management Independence, Ohio $17.7B AUM 18.87% 1-Year Est. Return
ASRS
Arizona State Retirement System Phoenix, Arizona $17.1B AUM 30.52% 1-Year Est. Return
PP
Prudential plc London, England, United Kingdom $17.1B AUM 15.7% 1-Year Est. Return
VMPIC
Varma Mutual Pension Insurance Co Helsinki, Finland $17B AUM 24.09% 1-Year Est. Return
LA
Linden Advisors New York $17.9B AUM 1.72% 1-Year Est. Return
BCIM
British Columbia Investment Management Victoria, British Columbia, Canada $17B AUM 31.69% 1-Year Est. Return

Baker Bros. Advisors's Q1 2024 Portfolio in Review

As of Q1 2024, Baker Bros. Advisors held 94 positions worth $7.97B, down 9.3% from $8.79B the previous quarter. Its ten largest holdings account for 77% of the portfolio.

Baker Bros. Advisors's Q1 2024 filing shows 12 new, 15 increased, 7 reduced and 7 closed positions. Its largest new stake was Fate Therapeutics: 1,818,181 shares worth $13.3M. The largest sale was Mirati Therapeutics, Inc. Common Stock, an estimated $242M.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, up from 98% a quarter earlier, followed by Financials.

  • Baker Bros. Advisors's largest Q1 2024 buy was Fate Therapeutics: 1,818,181 shares worth $13.3M.
  • Baker Bros. Advisors added most to Revolution Medicines in Q1 2024, an estimated $71.2M increase.
  • Baker Bros. Advisors's biggest Q1 2024 reduction was Immunocore, cutting an estimated $69M.
  • Baker Bros. Advisors fully exited Mirati Therapeutics, Inc. Common Stock in Q1 2024, selling an estimated $242M.
  • Baker Bros. Advisors's ten largest holdings make up 77% of its $7.97B portfolio in Q1 2024.
  • Baker Bros. Advisors opened 12 new positions and closed 7 in Q1 2024.
  • Baker Bros. Advisors's portfolio value fell 9.3% quarter-over-quarter to $7.97B.

Based on Baker Bros. Advisors's 13F filing for Q1 2024, filed 15 May 2024.